bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary Table 1 from Integrative Array-Based Approach Identifies MZB1 as a Frequently Methylated Putative Tumor Suppressor in Hepatocellular Carcinoma
Authors: Matsumura Satoshi , Imoto Issei , Kozaki Ken-ichi , Matsui Takeshi , Muramatsu Tomoki , Furuta Mayuko , Tanaka Shinji , Sakamoto Michiie , Arii Shigeki , Inazawa Johji
Published: April 2023

PDF file, 37KB, Primers for COBRA and bisulfite sequencing(bisulfite-PCR).
Supplementary Tables 1 - 3 from VEGF/VEGFR-2 Upregulates EZH2 Expression in Lung Adenocarcinoma Cells and EZH2 Depletion Enhances the Response to Platinum-Based and VEGFR-2–Targeted Therapy
Authors: Riquelme Erick , Suraokar Milind , Behrens Carmen , Lin Heather Y. , Girard Luc , Nilsson Monique B. , Simon George , Wang Jing , Coombes Kevin R. , Lee J. Jack , Hong Waun Ki , Heymach John , Minna John D. , Wistuba Ignacio I.
Published: April 2023

PDF file - 136KB, Supplementary Table 1. Sumary of the clinicopathological characteristics of the patients with lung adecarcinomas examined for EZH2 and miR-101 expressions. Supplementary Table 2. Association between markers' expression and lung adenocarcinoma patient's clinical and pathological characteristics. Supplementary Table 3. Summary of Multivariate Analysis of Outcome in Lung Adenocarcinoma Patients by Adjuvant Chemoterapy and EZH2, miR-101 and Combination of EZH2/miR-101 Expression.
Related Article from Evaluating a Marker's Contribution to a Nomogram: The GEMCaP Example
Authors: Kattan Michael W.
Published: April 2023

Related Article from Evaluating a Marker's Contribution to a Nomogram: The GEMCaP Example
Supplementary Figure Legend from Tumor-Associated Macrophages in Pediatric Classical Hodgkin Lymphoma: Association with Epstein-Barr Virus, Lymphocyte Subsets, and Prognostic Impact
Authors: Barros Mário Henrique M. , Hassan Rocio , Niedobitek Gerald
Published: April 2023

PDF file, 39KB.
Supplementary Figure 1 from PIK3CA/PTEN Mutations and Akt Activation As Markers of Sensitivity to Allosteric mTOR Inhibitors
Authors: Meric-Bernstam Funda , Akcakanat Argun , Chen Huiqin , Do Kim-Anh , Sangai Takafumi , Adkins Farrell , Gonzalez-Angulo Ana Maria , Rashid Asif , Crosby Katherine , Dong Mei , Phan Alexandria T. , Wolff Robert A. , Gupta Sanjay , Mills Gordon B. , Yao James
Published: April 2023

PDF file - 158K
Supplementary Figure 5 from Synthetic miR-34a Mimics as a Novel Therapeutic Agent for Multiple Myeloma: In Vitro and In Vivo Evidence
Authors: Di Martino Maria T. , Leone Emanuela , Amodio Nicola , Foresta Umberto , Lionetti Marta , Pitari Maria R. , Cantafio Maria E. Gallo , Gullà Annamaria , Conforti Francesco , Morelli Eugenio , Tomaino Vera , Rossi Marco , Negrini Massimo , Ferrarini Manlio , Caraglia Michele , Shammas Masood A. , Munshi Nikhil C. , Anderson Kenneth C. , Neri Antonino , Tagliaferri Pierosandro , Tassone Pierfrancesco
Published: April 2023

PDF file - 78K, Quantitative analysis of miR-34a levels in retrieved tumors
Supplementary Figure Legend from Superior Efficacy of a Combined Epigenetic Therapy against Human Mantle Cell Lymphoma Cells
Authors: Fiskus Warren , Rao Rekha , Balusu Ramesh , Ganguly Siddhartha , Tao Jianguo , Sotomayor Eduardo , Mudunuru Uma , Smith Jacqueline E. , Hembruff Stacey L. , Atadja Peter , Marquez Victor E. , Bhalla Kapil
Published: April 2023

PDF file, 83K.
Supplementary Table 1 from A Multicenter Phase I Trial of PX-866, an Oral Irreversible Phosphatidylinositol 3-Kinase Inhibitor, in Patients with Advanced Solid Tumors
Authors: Hong David S. , Bowles Daniel W. , Falchook Gerald S. , Messersmith Wells A. , George Goldy C. , O'Bryant Cindy L. , Vo Alex C. H. , Klucher Kevin , Herbst Roy S. , Eckhardt S. Gail , Peterson Scott , Hausman Diana F. , Kurzrock Razelle , Jimeno Antonio
Published: April 2023

PDF file, 54KB, Mutational Status for Arm 1.
Supplementary Table 1 from Analysis of Spontaneous Tumor-Specific CD4 T-cell Immunity in Lung Cancer Using Promiscuous HLA-DR Telomerase-Derived Epitopes: Potential Synergistic Effect with Chemotherapy Response
Authors: Godet Yann , Fabre Elizabeth , Dosset Magalie , Lamuraglia Michele , Levionnois Emeline , Ravel Patrice , Benhamouda Nadine , Cazes Aurélie , Le Pimpec-Barthes Françoise , Gaugler Beatrice , Langlade-Demoyen Pierre , Pivot Xavier , Saas Philippe , Maillère Bernard , Tartour Eric , Borg Christophe , Adotévi Olivier
Published: April 2023

XLS file - 8K
Supplementary Figure 3 from Prolonged Inhibition of Glioblastoma Xenograft Initiation and Clonogenic Growth following In Vivo Notch Blockade
Authors: Chu Qian , Orr Brent A. , Semenkow Samantha , Bar Eli E. , Eberhart Charles G.
Published: April 2023

PDF file - 127K, Cell cycle analysis was performed in triplicate on HSR-GBM1 XG2-derived neurospheres and analyzed on a Guava PCA.
Supplementary Figure Legend 1 from Genome-Wide miRNA Expression Profiling Identifies miR-9-3 and miR-193a as Targets for DNA Methylation in Non–Small Cell Lung Cancers
Authors: Heller Gerwin , Weinzierl Marlene , Noll Christian , Babinsky Valerie , Ziegler Barbara , Altenberger Corinna , Minichsdorfer Christoph , Lang György , Döme Balazs , End-Pfützenreuter Adelheid , Arns Britt-Madeleine , Grin Yuliya , Klepetko Walter , Zielinski Christoph C. , Zöchbauer-Müller Sabine
Published: April 2023

PDF file - 43K
Supplementary Figure Legends 1 from Early [18F]Fluorodeoxyglucose Positron Emission Tomography at Two Days of Gefitinib Treatment Predicts Clinical Outcome in Patients with Adenocarcinoma of the Lung
Authors: Takahashi Ryo , Hirata Haruhiko , Tachibana Isao , Shimosegawa Eku , Inoue Atsuo , Nagatomo Izumi , Takeda Yoshito , Kida Hiroshi , Goya Sho , Kijima Takashi , Yoshida Mitsuhiro , Kumagai Toru , Kumanogoh Atsushi , Okumura Meinoshin , Hatazawa Jun , Kawase Ichiro
Published: April 2023

PDF file - 73K
Supplementary Figure S1 from microRNA 223 Is Upregulated in the Multistep Progression of Barrett's Esophagus and Modulates Sensitivity to Chemotherapy by Targeting PARP1
Authors: Streppel Mirte Mayke , Pai Shweta , Campbell Nathaniel R. , Hu Chaoxin , Yabuuchi Shinichi , Canto Marcia Irene , Wang Jean S. , Montgomery Elizabeth A. , Maitra Anirban
Published: April 2023

Supplementary Figure S1 - PDF file 28K, This file contains supplementary figure S1. An overview of the study design for miR validation using FFPE and frozen specimens is provided in this flowchart
Supplementary Table 1, Figures 1 - 2 from The Janus Kinases Inhibitor AZD1480 Attenuates Growth of Small Cell Lung Cancers In Vitro and In Vivo
Authors: Lee Jih-Hsiang , Park Kang-Seo , Alberobello Anna Teresa , Kallakury Bhaskar , Weng Meng-Tzu , Wang Yisong , Giaccone Giuseppe
Published: April 2023

PDF file - 192K, Table S1. JAK2 copy number, relative mRNA expression, relative protein expression and IC50 to AZD1480 in SCLC cells. Figure S1. Relationship between IC50 of SCLC cells to AZD1480 and protein expression of JAK1, JAK2, and STAT3. Figure S2. Knocking-down JAK1 or JAK2 in NCI-H82 or GLC4 SCLC cells.
Supplementary Figure Legend from Pretreatment EBV-DNA Copy Number Is Predictive of Response and Toxicities to SMILE Chemotherapy for Extranodal NK/T-cell Lymphoma, Nasal Type
Authors: Ito Yoshinori , Kimura Hiroshi , Maeda Yoshinobu , Hashimoto Chizuko , Ishida Fumihiro , Izutsu Koji , Fukushima Noriyasu , Isobe Yasushi , Takizawa Jun , Hasegawa Yuichi , Kobayashi Hajime , Okamura Seiichi , Kobayashi Hikaru , Yamaguchi Motoko , Suzumiya Junji , Hyo Rie , Nakamura Shigeo , Kawa Keisei , Oshimi Kazuo , Suzuki Ritsuro
Published: April 2023

PDF file - 64K
Supplementary Figure 1 from Pretreatment EBV-DNA Copy Number Is Predictive of Response and Toxicities to SMILE Chemotherapy for Extranodal NK/T-cell Lymphoma, Nasal Type
Authors: Ito Yoshinori , Kimura Hiroshi , Maeda Yoshinobu , Hashimoto Chizuko , Ishida Fumihiro , Izutsu Koji , Fukushima Noriyasu , Isobe Yasushi , Takizawa Jun , Hasegawa Yuichi , Kobayashi Hajime , Okamura Seiichi , Kobayashi Hikaru , Yamaguchi Motoko , Suzumiya Junji , Hyo Rie , Nakamura Shigeo , Kawa Keisei , Oshimi Kazuo , Suzuki Ritsuro
Published: April 2023

PDF file - 86K, 4.Correlation of EBER positivity and EBV-DNA levels in whole blood or plasma
Supplementary Figure 1 from A Randomized, Multicenter, Placebo-Controlled Clinical Trial of Racotumomab-Alum Vaccine as Switch Maintenance Therapy in Advanced Non–Small Cell Lung Cancer Patients
Authors: Alfonso Sailyn , Valdés-Zayas Anet , Santiesteban Eduardo R. , Flores Yoanna I. , Areces Fernando , Hernández Maurenis , Viada Carmen E. , Mendoza Ivis C. , Guerra Pedro P. , García Elena , Ortiz Ramón A. , de la Torre Ana V. , Cepeda Meylán , Pérez Kirenia , Chong Eric , Hernández Ana María , Toledo Darien , González Zuyén , Mazorra Zaima , Crombet Tania , Pérez Rolando , Vázquez Ana María , Macías Amparo E.
Published: April 2023

PDF file - 284KB, CONSORT study diagram.
Related Article from The Antitumor Immunity of Ipilimumab: (T-cell) Memories to Last a Lifetime?
Authors: Postow Michael A. , Callahan Margaret K. , Wolchok Jedd D.
Published: April 2023

Related Article from The Antitumor Immunity of Ipilimumab: (T-cell) Memories to Last a Lifetime?
Supplementary Table 1 from KRAS and BRAF Mutations Predict Primary Resistance to Imatinib in Gastrointestinal Stromal Tumors
Authors: Miranda Claudia , Nucifora Martina , Molinari Francesca , Conca Elena , Anania Maria Chiara , Bordoni Andrea , Saletti Piercarlo , Mazzucchelli Luca , Pilotti Silvana , Pierotti Marco A. , Tamborini Elena , Greco Angela , Frattini Milo
Published: April 2023

PDF file - 76K, Swiss GIST case material.
Related Article from The Importance of Doing Trials Right While Doing the Right Trials
Authors: Dilts David M. , Cheng Steven K.
Published: April 2023

Related Article from The Importance of Doing Trials Right While Doing the Right Trials
Figure S4 from Reprogramming Metabolism with Metformin Improves Tumor Oxygenation and Radiotherapy Response
Authors: Zannella Vanessa E. , Dal Pra Alan , Muaddi Hala , McKee Trevor D. , Stapleton Shawn , Sykes Jenna , Glicksman Rachel , Chaib Selim , Zamiara Paul , Milosevic Michael , Wouters Bradly G. , Bristow Robert G. , Koritzinsky Marianne
Published: April 2023

PDF file 92K, Figure S4 shows the effect of metformin on bRFR in the matched cohort of 172 prostate cancer patients
Supplementary Figure Legend from Ki67 Measured after Neoadjuvant Chemotherapy for Primary Breast Cancer
Authors: von Minckwitz Gunter , Schmitt Wolfgang D. , Loibl Sibylle , Müller Berit M. , Blohmer Jens U. , Sinn Bruno V. , Eidtmann Holger , Eiermann Wolfgang , Gerber Bernd , Tesch Hans , Hilfrich Jörn , Huober Jens , Fehm Tanja , Barinoff Jana , Rüdiger Thomas , Erbstoesser Erhard , Fasching Peter A. , Karn Thomas , Müller Volkmar , Jackisch Christian , Denkert Carsten
Published: April 2023

PDF file, 22K.
Supplementary Tables 1 - 3 from Profiles of Genomic Instability in High-Grade Serous Ovarian Cancer Predict Treatment Outcome
Authors: Wang Zhigang C. , Birkbak Nicolai Juul , Culhane Aedín C. , Drapkin Ronny , Fatima Aquila , Tian Ruiyang , Schwede Matthew , Alsop Kathryn , Daniels Kathryn E. , Piao Huiying , Liu Joyce , Etemadmoghadam Dariush , Miron Alexander , Salvesen Helga B. , Mitchell Gillian , DeFazio Anna , Quackenbush John , Berkowitz Ross S. , Iglehart J. Dirk , Bowtell David D.L. , Matulonis Ursula A.
Published: April 2023

XLS file, 509K, supplementary Tables 1-3: 1. Information from the Boston cohort, 2. Information from AOCS cohort, 3. Information from TCGA.
Supplementary Table 3 from A Comparative and Integrative Approach Identifies ATPase Family, AAA Domain Containing 2 as a Likely Driver of Cell Proliferation in Lung Adenocarcinoma
Authors: Fouret Robert , Laffaire Julien , Hofman Paul , Beau-Faller Michèle , Mazieres Julien , Validire Pierre , Girard Philippe , Camilleri-Bröet Sophie , Vaylet Fabien , Leroy-Ladurie François , Soria Jean-Charles , Fouret Pierre
Published: April 2023

PDF file, 40K, Correlation of cluster f mitotic spindle genes with ATAD2 or MYC in the LG cohort.
Supplementary Figure 3 from A Comparative and Integrative Approach Identifies ATPase Family, AAA Domain Containing 2 as a Likely Driver of Cell Proliferation in Lung Adenocarcinoma
Authors: Fouret Robert , Laffaire Julien , Hofman Paul , Beau-Faller Michèle , Mazieres Julien , Validire Pierre , Girard Philippe , Camilleri-Bröet Sophie , Vaylet Fabien , Leroy-Ladurie François , Soria Jean-Charles , Fouret Pierre
Published: April 2023

PDF file, 528K, Overview of module 1 to 27 profiles. Samples are sorted according to the regulatory programs found with CONEXIC in the LG cohort.
Supplementary Figure 1 from A Comparative and Integrative Approach Identifies ATPase Family, AAA Domain Containing 2 as a Likely Driver of Cell Proliferation in Lung Adenocarcinoma
Authors: Fouret Robert , Laffaire Julien , Hofman Paul , Beau-Faller Michèle , Mazieres Julien , Validire Pierre , Girard Philippe , Camilleri-Bröet Sophie , Vaylet Fabien , Leroy-Ladurie François , Soria Jean-Charles , Fouret Pierre
Published: April 2023

PDF file, 188K, Module network views of the original and the modified module 62 in the 68 lung adenocarcinomas from the Ding cohort (GSE12667) and of the modified module 62 in the LG cohort.
Supplementary Figure 1B from Integrated Analysis Reveals Critical Genomic Regions in Prostate Tumor Microenvironment Associated with Clinicopathologic Phenotypes
Authors: Ashida Shingo , Orloff Mohammed S. , Bebek Gurkan , Zhang Li , Zheng Pan , Peehl Donna M. , Eng Charis
Published: April 2023

PDF file - 25K
Supplementary Table 6 from A Signature Predicting Poor Prognosis in Gastric and Ovarian Cancer Represents a Coordinated Macrophage and Stromal Response
Authors: Busuttil Rita A. , George Joshy , Tothill Richard W. , Ioculano Kylie , Kowalczyk Adam , Mitchell Catherine , Lade Stephen , Tan Patrick , Haviv Izhak , Boussioutas Alex
Published: April 2023

XLS file - 28KB, Compartmental locations of cluster 27 genes in GC and OVCA.
Supplementary Table 5 from A Signature Predicting Poor Prognosis in Gastric and Ovarian Cancer Represents a Coordinated Macrophage and Stromal Response
Authors: Busuttil Rita A. , George Joshy , Tothill Richard W. , Ioculano Kylie , Kowalczyk Adam , Mitchell Catherine , Lade Stephen , Tan Patrick , Haviv Izhak , Boussioutas Alex
Published: April 2023

XLS file - 22KB, Ontological enrichment in epithelial and stromal compartments in PMCC_gastric datset.
Supplementary Tables 1 - 2 from A Phase II and Biomarker Study of Ramucirumab, a Human Monoclonal Antibody Targeting the VEGF Receptor-2, as First-Line Monotherapy in Patients with Advanced Hepatocellular Cancer
Authors: Zhu Andrew X. , Finn Richard S. , Mulcahy Mary , Gurtler Jayne , Sun Weijing , Schwartz Jonathan D. , Dalal Rita P. , Joshi Adarsh , Hozak Rebecca R. , Xu Yihuan , Ancukiewicz Marek , Jain Rakesh K. , Nugent Francis W. , Duda Dan G. , Stuart Keith
Published: April 2023

PDF file - 91K, Table S1.Fold changes in serum biomarkers relative to baseline following ramucirumabtreatment (MGH lab) Table S2: Changes in serum biomarkers relative to baseline following ramucirumab treatment (ImClonelab).
Supplementary Figure 2 from A Phase II and Biomarker Study of Ramucirumab, a Human Monoclonal Antibody Targeting the VEGF Receptor-2, as First-Line Monotherapy in Patients with Advanced Hepatocellular Cancer
Authors: Zhu Andrew X. , Finn Richard S. , Mulcahy Mary , Gurtler Jayne , Sun Weijing , Schwartz Jonathan D. , Dalal Rita P. , Joshi Adarsh , Hozak Rebecca R. , Xu Yihuan , Ancukiewicz Marek , Jain Rakesh K. , Nugent Francis W. , Duda Dan G. , Stuart Keith
Published: April 2023

PDF file - 23K, Waterfall plot depicting the percent change from baseline in serum in alphafetoprotein (AFP)and treatment response in HCC patients after ramucirumab monotherapy. PR, partial response; SD, stable disease; PD, progressive disease; NE, not evaluated.
Supplementary Figure 1 from A Phase II and Biomarker Study of Ramucirumab, a Human Monoclonal Antibody Targeting the VEGF Receptor-2, as First-Line Monotherapy in Patients with Advanced Hepatocellular Cancer
Authors: Zhu Andrew X. , Finn Richard S. , Mulcahy Mary , Gurtler Jayne , Sun Weijing , Schwartz Jonathan D. , Dalal Rita P. , Joshi Adarsh , Hozak Rebecca R. , Xu Yihuan , Ancukiewicz Marek , Jain Rakesh K. , Nugent Francis W. , Duda Dan G. , Stuart Keith
Published: April 2023

PDF file - 143K, Kaplan-Meier survival distributions of progression-free survival, overall survival by type of antihypertensive treatment, and Time-to-event curve for first JNC 7 stage 1 or greater hypertension.
CCR Translation for This Article from Toward Prediction of Efficacy of Chemotherapy: A Proof of Concept Study in Lung Cancer Patients Using [11C]docetaxel and Positron Emission Tomography
Authors: van der Veldt Astrid A.M. , Lubberink Mark , Mathijssen Ron H.J. , Loos Walter J. , Herder Gerarda J.M. , Greuter Henri N. , Comans Emile F.I. , Rutten Hugo B. , Eriksson Jonas , Windhorst Albert D. , Hendrikse N. Harry , Postmus Pieter E. , Smit Egbert F. , Lammertsma Adriaan A.
Published: April 2023

CCR Translation for This Article from Toward Prediction of Efficacy of Chemotherapy: A Proof of Concept Study in Lung Cancer Patients Using [11C]docetaxel and Positron Emission Tomography
Supplementary Figure 3 from Blocked Autophagy Using Lysosomotropic Agents Sensitizes Resistant Prostate Tumor Cells to the Novel Akt Inhibitor AZD5363
Authors: Lamoureux Francois , Thomas Christian , Crafter Claire , Kumano Masafumi , Zhang Fan , Davies Barry R. , Gleave Martin E. , Zoubeidi Amina
Published: April 2023

PDF file - 74 KB, Targeting autophagy enhances PI-103 activity to induce apoptosis in PC-3 tumor prostate cells.
Supplementary Table 2 from Lactate Dehydrogenase B Is Required for the Growth of KRAS-Dependent Lung Adenocarcinomas
Authors: McCleland Mark L. , Adler Adam S. , Deming Laura , Cosino Ely , Lee Leslie , Blackwood Elizabeth M. , Solon Margaret , Tao Janet , Li Li , Shames David , Jackson Erica , Forrest William F. , Firestein Ron
Published: April 2023

XLS file - 12K, KRAS mutation status and copy number of KRAS and LDHB in NSCLC cell lines
Supplementary Table 1 from Lactate Dehydrogenase B Is Required for the Growth of KRAS-Dependent Lung Adenocarcinomas
Authors: McCleland Mark L. , Adler Adam S. , Deming Laura , Cosino Ely , Lee Leslie , Blackwood Elizabeth M. , Solon Margaret , Tao Janet , Li Li , Shames David , Jackson Erica , Forrest William F. , Firestein Ron
Published: April 2023

XLS file - 22K, Significance and frequency of KRAS amplification across multiple cancer types
Supplementary Figure Legend from Lactate Dehydrogenase B Is Required for the Growth of KRAS-Dependent Lung Adenocarcinomas
Authors: McCleland Mark L. , Adler Adam S. , Deming Laura , Cosino Ely , Lee Leslie , Blackwood Elizabeth M. , Solon Margaret , Tao Janet , Li Li , Shames David , Jackson Erica , Forrest William F. , Firestein Ron
Published: April 2023

PDF file - 110K
Supplementary Figure 4 from COX-2–Independent Effects of Celecoxib Sensitize Lymphoma B Cells to TRAIL-Mediated Apoptosis
Authors: Gallouet Anne-Sophie , Travert Marion , Bresson-Bepoldin Laurence , Guilloton Fabien , Pangault Céline , Caulet-Maugendre Sylvie , Lamy Thierry , Tarte Karin , Guillaudeux Thierry
Published: April 2023

PDF file - 75K,(A) Expression of the 4 EP receptors (PGE2 receptors) in BL2 and SUDHL4 was evaluated by western blotting. (B) and (C) BL2 and SUDHL4 were cultured with X-VIVO medium and stimulated with PGE2 for 24h. (B) B cell proliferation was evaluated with tritiated thymidine (3H-TdR) incorporation. Results from one of three representative experiments. Mean plus-minus SD. (C) After PGE2 stimulation for 1h, BL2 and SUDHL4 were treated or not with 100ng/ml TRAIL for 24h. Apoptotic B cells were analysed by flow cytometry using CD19pos, CD20pos and active caspase-3 staining.
Supplementary Figure 4 from Lactate Dehydrogenase B Is Required for the Growth of KRAS-Dependent Lung Adenocarcinomas
Authors: McCleland Mark L. , Adler Adam S. , Deming Laura , Cosino Ely , Lee Leslie , Blackwood Elizabeth M. , Solon Margaret , Tao Janet , Li Li , Shames David , Jackson Erica , Forrest William F. , Firestein Ron
Published: April 2023

PDF file - 214K, LDHB expression and dependence in lung adenocarcinoma cell lines containing various oncogenic drivers
Supplementary Figure 2 from COX-2–Independent Effects of Celecoxib Sensitize Lymphoma B Cells to TRAIL-Mediated Apoptosis
Authors: Gallouet Anne-Sophie , Travert Marion , Bresson-Bepoldin Laurence , Guilloton Fabien , Pangault Céline , Caulet-Maugendre Sylvie , Lamy Thierry , Tarte Karin , Guillaudeux Thierry
Published: April 2023

PDF file - 34K, HD-MSC were cultured at 0.5x105 cells/cm2. After 3 days, 105 cells of NHL-B cells lines were seeded on these stromal cells and stimulated or not with 30�M celecoxib and/or 50ng/ml of TRAIL. B cell apoptosis was analyzed by flow cytometry gating on CD19posCD20posCD105neg active capsase-3pos cells. Apoptosis level of B cell lines without stromal cells (figure 2) was reported with dotted lines Mean plus-minus SD, n=2.
Supplementary Figure 1 from Lactate Dehydrogenase B Is Required for the Growth of KRAS-Dependent Lung Adenocarcinomas
Authors: McCleland Mark L. , Adler Adam S. , Deming Laura , Cosino Ely , Lee Leslie , Blackwood Elizabeth M. , Solon Margaret , Tao Janet , Li Li , Shames David , Jackson Erica , Forrest William F. , Firestein Ron
Published: April 2023

PDF file - 155K, Validation of mRNA knockdown of candidate genes in the RNAi screen
Supplementary Data from Prognostic Relevance of Circulating Tumor Cells in Blood and Disseminated Tumor Cells in Bone Marrow of Patients with Squamous Cell Carcinoma of the Oral Cavity
Authors: Gröbe Alexander , Blessmann Marco , Hanken Henning , Friedrich Reinhard E. , Schön Gerhard , Wikner Johannes , Effenberger Katharina E. , Kluwe Lan , Heiland Max , Pantel Klaus , Riethdorf Sabine
Published: April 2023

PDF file 404K, Supplementary Table 1: Detailed information for each CTC-positive patient regarding tumor size (T-stage), lymph node involvement (N-stage) and distant metastasis (M-stage) at diagnosis and number of CTCs/7.5 mL blood. Supplementary Table 2: Detailed information for each DTC-positive patient regarding tumor size (T-stage), lymph node involvement (N-stage) and distant metastasis (M-stage) at diagnosis and number of DTCs/2x106 mononuclear cells. Supplementary Figure 1: Gallery of CTC images generated with the CellSearch system from cases #1-10 equivalent to Patient ID in Supplementary Table 1. Supplementary Figure 2: Time to relapse for CTC-positive patients by adjuvant therapy (none, radiotherapy, radiochemotherapie, A left), A right: Time to relapse for CTC-negative patients by adjuvant therapy (none, radiotherapy, radiochemotherapie); B left: Time to relapse for DTC-positive patients by adjuvant therapy (none, radiotherapy, radiochemotherapie), right: Time to relapse for DTC-negative patients by adjuvant therapy (none, radiotherapy, radiochemotherapie) Supplementary Figure 3: Time to locoregional relapse for CTC-positive patients without metastatic disease at diagnosis (A); Time to locoregional relapse for DTC-positive patients without metastatic disease at diagnosis (B) Supplementary Figure 4: Gallery of detected DTCs from cases #1-18 equivalent to Patient ID in Supplementary Table 2
Table S1 from Targeting Treatment-Resistant Breast Cancer Stem Cells with FKBPL and Its Peptide Derivative, AD-01, via the CD44 Pathway
Authors: McClements Lana , Yakkundi Anita , Papaspyropoulos Angelos , Harrison Hannah , Ablett Matthew P. , Jithesh Puthen V. , McKeen Hayley D. , Bennett Rachel , Donley Christopher , Kissenpfennig Adrien , McIntosh Stuart , McCarthy Helen O. , O'Neill Eric , Clarke Robert B. , Robson Tracy
Published: April 2023

Table S1 - PDF file 66K, Percentage ESA+/CD44+/CD24- or ALDH+ cells gated using flow cytometry (n=3)
Supplementary Figure 4 from Tumor-Specific Isoform Switch of the Fibroblast Growth Factor Receptor 2 Underlies the Mesenchymal and Malignant Phenotypes of Clear Cell Renal Cell Carcinomas
Authors: Zhao Qi , Caballero Otavia L. , Davis Ian D. , Jonasch Eric , Tamboli Pheroze , Yung W.K. Alfred , Weinstein John N. , Strausberg Robert L. , Yao Jun
Published: April 2023

PDF file - 431K, FGFR2 promoter DNA methylation near exon 1 correlated with reduced FGFR2 expression
Supplementary Table S8 from Effect of Aromatase Inhibition on Functional Gene Modules in Estrogen Receptor–Positive Breast Cancer and Their Relationship with Antiproliferative Response
Authors: Gao Qiong , Patani Neill , Dunbier Anita K. , Ghazoui Zara , Zvelebil Marketa , Martin Lesley-Ann , Dowsett Mitch
Published: April 2023

Summary of cluster stability analysis of unsupervised hierarchical clustering of gene module scores at pre, during, post treatment using the pvclust.
Supplementary Figure 4 from Neutrophils Promote the Malignant Glioma Phenotype through S100A4
Authors: Liang Ji , Piao Yuji , Holmes Lindsay , Fuller Gregory N. , Henry Verlene , Tiao Ningyi , de Groot John F.
Published: April 2023

PDF file 177K, S100A4 expression correlates with the survival curve of glioblatoma patients
Supplementary Table S4 from Effect of Aromatase Inhibition on Functional Gene Modules in Estrogen Receptor–Positive Breast Cancer and Their Relationship with Antiproliferative Response
Authors: Gao Qiong , Patani Neill , Dunbier Anita K. , Ghazoui Zara , Zvelebil Marketa , Martin Lesley-Ann , Dowsett Mitch
Published: April 2023

This details the genes that comprise each gene module used in this analysis.
Supplementary Figure 2 from Neutrophils Promote the Malignant Glioma Phenotype through S100A4
Authors: Liang Ji , Piao Yuji , Holmes Lindsay , Fuller Gregory N. , Henry Verlene , Tiao Ningyi , de Groot John F.
Published: April 2023

PDF file 71K, Microarray analysis by IPA for the characteristics changes of GIC11 cells when co-culture of MPRO cells
Supplementary File S6 from Effect of Aromatase Inhibition on Functional Gene Modules in Estrogen Receptor–Positive Breast Cancer and Their Relationship with Antiproliferative Response
Authors: Gao Qiong , Patani Neill , Dunbier Anita K. , Ghazoui Zara , Zvelebil Marketa , Martin Lesley-Ann , Dowsett Mitch
Published: April 2023

Analysis results of assessing the effect of the impact of the gene expression of PAGs on FAIMoS dataset and their association with Ki67 protein expression.
Supplementary Fig S5 from Targeting CD73 Enhances the Antitumor Activity of Anti-PD-1 and Anti-CTLA-4 mAbs
Authors: Allard Bertrand , Pommey Sandra , Smyth Mark J. , Stagg John
Published: April 2023

Supplementary Fig S5 - PDF file 51K, Figure S5. PD-1 and CTLA-4 expression levels in TILs after anti-CD73 mAb treatment
Supplementary Table 2 from A Comparative Analysis of Prognostic Factor Models for Follicular Lymphoma Based on a Phase III Trial of CHOP–Rituximab versus CHOP + 131Iodine—Tositumomab
Authors: Press Oliver W. , Unger Joseph M. , Rimsza Lisa M. , Friedberg Jonathan W. , LeBlanc Michael , Czuczman Myron S. , Kaminski Mark , Braziel Rita M. , Spier Catherine , Gopal Ajay K. , Maloney David G. , Cheson Bruce D. , Dakhil Shaker R. , Miller Thomas P. , Fisher Richard I.
Published: April 2023

PDF file 54K, Supplementary Table 2: Distribution of Risk Groups in Intergroup Trial S0016 and in Selected Other Recent Major Trials of Advanced Follicular Lymphoma
Supplementary Table 2 from The Immune Signature of CD8+CCR7+ T Cells in the Peripheral Circulation Associates with Disease Recurrence in Patients with HNSCC
Authors: Czystowska Malgorzata , Gooding William , Szczepanski Miroslaw J. , Lopez-Abaitero Andres , Ferris Robert L. , Johnson Jonas T. , Whiteside Theresa L.
Published: April 2023

PDF file - 57 KB, Results of the experimental verification of the two predictive models
Figure S4 from Targeting Src and Tubulin in Mucinous Ovarian Carcinoma
Authors: Liu Tao , Hu Wei , Dalton Heather J. , Choi Hyun Jin , Huang Jie , Kang Yu , Pradeep Sunila , Miyake Takahito , Song Jian H. , Wen Yunfei , Lu Chunhua , Pecot Chad V. , Bottsford-Miller Justin , Zand Behrouz , Jennings Nicholas B. , Ivan Cristina , Gallick Gary E. , Baggerly Keith A. , Hangauer David G. , Coleman Robert L. , Frumovitz Michael , Sood Anil K.
Published: April 2023

PDF file 176K, Figure S4. The effect of Src inhibitor or paclitaxel on cell survival. Cell survival was calculated as the number of cells surviving relative to the number of cells surviving in the control group. IC50 6 indicates median inhibitory rate. (A, B) MTT assay results showing the cytotoxicity of PP2 and paclitaxel at various concentrations in RMUG-S cells. (C, D, E) The cytotoxicity of Src siRNA, PP2 or paclitaxel in combination with oxaliplatin in the RMUG-S cells
Related Article from CD137 as a Biomarker for Tumor-Reactive T Cells: Finding Gold in the Desert
Authors: Zhu Yuwen , Chen Lieping
Published: April 2023

Related Article from CD137 as a Biomarker for Tumor-Reactive T Cells: Finding Gold in the Desert
Supplementary Figure 1 from Tumor Suppressive Effects of Bromodomain-Containing Protein 7 (BRD7) in Epithelial Ovarian Carcinoma
Authors: Park Young-Ae , Lee Jeong-Won , Kim Hye-Sun , Lee Yoo-Young , Kim Tae-Joong , Choi Chel Hun , Choi Jung-Joo , Jeon Hye-Kyung , Cho Young Jae , Ryu Ji Yoon , Kim Byoung-Gie , Bae Duk-Soo
Published: April 2023

PDF - 1513K, BRD7 mediated tumor suppressive effects are not correlated with cell cycle. A, Cell cycle distributions of A2780 (marked as A) and SKOV3 (marked as S) cells measured by flow cytometry. Cell number histograms plot (upper panel) show the distribution of cells on the basis of DNA contents as determined by PI fluorescence intensity. Left peak represents cells in the G1/G0 phases, hatched area represents cells in S phase, and peak on right represents cells in the G2 and M phases. The expression levels of BRD7 mRNA among phases of cell cycle show no significant differences in both A2780 and SKOV3 cell line (.lower panel). Values are expressed as means of three independent experiments plus or minus SD. B, Western blot analysis was used to determine expression levels of Cyclin B1, D1 or E2.
Supplementary Table 5 from Functional Heterogeneity of Cancer-Associated Fibroblasts from Human Colon Tumors Shows Specific Prognostic Gene Expression Signature
Authors: Herrera Mercedes , Islam Abul B.M.M.K. , Herrera Alberto , Martín Paloma , García Vanesa , Silva Javier , Garcia Jose M. , Salas Clara , Casal Ignacio , de Herreros Antonio García , Bonilla Félix , Peña Cristina
Published: April 2023

XLS file - 3976K, Statistical detail of enrichment analysis of Gene Ontology Biological Process (GOBP) categories.
Supplementary Tables 1 - 2 from Profound Prevention of Experimental Brain Metastases of Breast Cancer by Temozolomide in an MGMT-Dependent Manner
Authors: Palmieri Diane , Duchnowska Renata , Woditschka Stephan , Hua Emily , Qian Yongzhen , Biernat Wojciech , Sosińska-Mielcarek Katarzyna , Gril Brunilde , Stark Andreas M. , Hewitt Stephen M. , Liewehr David J. , Steinberg Seth M. , Jassem Jacek , Steeg Patricia S.
Published: April 2023

PDF file - 88KB, Supplementary Table 1. Cross-tabulation of MGMT IHC staining in matched primary breast tumors and resected brain metastases using four categories. Supplementary Table 2. Association of MGMT staining and clinical variables with overall survival.
Supplementary Figure 5 from Functional Heterogeneity of Cancer-Associated Fibroblasts from Human Colon Tumors Shows Specific Prognostic Gene Expression Signature
Authors: Herrera Mercedes , Islam Abul B.M.M.K. , Herrera Alberto , Martín Paloma , García Vanesa , Silva Javier , Garcia Jose M. , Salas Clara , Casal Ignacio , de Herreros Antonio García , Bonilla Félix , Peña Cristina
Published: April 2023

PDF file - 5471K, Golgi-related gene module expression in colon cancer patients and its prognostic effect.
Supplementary Figure 3 from Functional Heterogeneity of Cancer-Associated Fibroblasts from Human Colon Tumors Shows Specific Prognostic Gene Expression Signature
Authors: Herrera Mercedes , Islam Abul B.M.M.K. , Herrera Alberto , Martín Paloma , García Vanesa , Silva Javier , Garcia Jose M. , Salas Clara , Casal Ignacio , de Herreros Antonio García , Bonilla Félix , Peña Cristina
Published: April 2023

PDF file - 1006K, CAF gene signature does not identify prognostic outcome in stage I-II patients.
Supplementary Figure 2 from Functional Heterogeneity of Cancer-Associated Fibroblasts from Human Colon Tumors Shows Specific Prognostic Gene Expression Signature
Authors: Herrera Mercedes , Islam Abul B.M.M.K. , Herrera Alberto , Martín Paloma , García Vanesa , Silva Javier , Garcia Jose M. , Salas Clara , Casal Ignacio , de Herreros Antonio García , Bonilla Félix , Peña Cristina
Published: April 2023

PDF file - 4340K, Differentially expressed genes of enriched GO functional categories.
Supplementary Figure 4 from Inhibition of DNA Double-Strand Break Repair by the Dual PI3K/mTOR Inhibitor NVP-BEZ235 as a Strategy for Radiosensitization of Glioblastoma
Authors: Gil del Alcazar Carlos Rodrigo , Hardebeck Molly Catherine , Mukherjee Bipasha , Tomimatsu Nozomi , Gao Xiaohuan , Yan Jingsheng , Xie Xian-Jin , Bachoo Robert , Li Li , Habib Amyn A. , Burma Sandeep
Published: April 2023

PDF file - 523K, NVP-BEZ235 inhibits the DDR in GBM9 neurospheres.
Supplementary Figure 1 from Functional Heterogeneity of Cancer-Associated Fibroblasts from Human Colon Tumors Shows Specific Prognostic Gene Expression Signature
Authors: Herrera Mercedes , Islam Abul B.M.M.K. , Herrera Alberto , Martín Paloma , García Vanesa , Silva Javier , Garcia Jose M. , Salas Clara , Casal Ignacio , de Herreros Antonio García , Bonilla Félix , Peña Cristina
Published: April 2023

PDF file - 1180K,CAF sub-culture passages. Comparison between CAF- and NF-derived paracrine pro-migratory effects on colon cancer cells. Analysis of CAFs' pluripotency by osteoblast differentiation.
Supplementary Figure Legend from Targeting of NAD Metabolism in Pancreatic Cancer Cells: Potential Novel Therapy for Pancreatic Tumors
Authors: Chini Claudia C.S. , Guerrico Anatilde M. Gonzalez , Nin Veronica , Camacho-Pereira Juliana , Escande Carlos , Barbosa Maria Thereza , Chini Eduardo N.
Published: April 2023

PDF file - 44K
Supplementary Figure 5 from Targeting of NAD Metabolism in Pancreatic Cancer Cells: Potential Novel Therapy for Pancreatic Tumors
Authors: Chini Claudia C.S. , Guerrico Anatilde M. Gonzalez , Nin Veronica , Camacho-Pereira Juliana , Escande Carlos , Barbosa Maria Thereza , Chini Eduardo N.
Published: April 2023

PDF file - 66K, CD38 overexpression increases sensitivity to FK866.
Supplementary Table 3 from Serum Antibodies to Blood Group A Predict Survival on PROSTVAC-VF
Authors: Campbell Christopher T. , Gulley James L. , Oyelaran Oyindasola , Hodge James W. , Schlom Jeffrey , Gildersleeve Jeffrey C.
Published: April 2023

PDF file - 58K, Secondary antibodies for fluorescent labeling of serum anti-glycan antibodies
Supplementary Table 1 from Serum Antibodies to Blood Group A Predict Survival on PROSTVAC-VF
Authors: Campbell Christopher T. , Gulley James L. , Oyelaran Oyindasola , Hodge James W. , Schlom Jeffrey , Gildersleeve Jeffrey C.
Published: April 2023

PDF file - 156K, Description of Array Components
Supplementary Table 1 from New Strategies for Triple-Negative Breast Cancer—Deciphering the Heterogeneity
Authors: Mayer Ingrid A. , Abramson Vandana G. , Lehmann Brian D. , Pietenpol Jennifer A.
Published: April 2023

XLSX file - 16075K, TNBCtype predictions for 163 primary tumors in TCGA considered to be TNBC.
Supplementary Methods, Tables 1 - 2 from PID1 (NYGGF4), a New Growth-Inhibitory Gene in Embryonal Brain Tumors and Gliomas
Authors: Erdreich-Epstein Anat , Robison Nathan , Ren Xiuhai , Zhou Hong , Xu Jingying , Davidson Tom B. , Schur Mathew , Gilles Floyd H. , Ji Lingyun , Malvar Jemily , Shackleford Gregory M. , Margol Ashley S. , Krieger Mark D. , Judkins Alexander R. , Jones David T.W. , Pfister Stefan M. , Kool Marcel , Sposto Richard , Asgharazadeh Shahab
Published: April 2023

PDF file - 440K, Supplemental Table 1: Characteristics of the CHLA Medulloblastoma Patients. Supplemental Table 2: Neural and Proneural GBM subgroups have higher PID1 mRNA compared to Classical and Mesenchymal.
Supplementary Figure 6 from PID1 (NYGGF4), a New Growth-Inhibitory Gene in Embryonal Brain Tumors and Gliomas
Authors: Erdreich-Epstein Anat , Robison Nathan , Ren Xiuhai , Zhou Hong , Xu Jingying , Davidson Tom B. , Schur Mathew , Gilles Floyd H. , Ji Lingyun , Malvar Jemily , Shackleford Gregory M. , Margol Ashley S. , Krieger Mark D. , Judkins Alexander R. , Jones David T.W. , Pfister Stefan M. , Kool Marcel , Sposto Richard , Asgharazadeh Shahab
Published: April 2023

PDF file - 25K, Supplemental Fig 6: PID1 diminishes phosphorylation of AKT and ERK in D283MED medulloblastoma cells grown in presence of serum.
Supplementary Figure 1 from Putative Predictive Biomarkers of Survival in Patients with Metastatic Pancreatic Adenocarcinoma Treated with Gemcitabine and Ganitumab, an IGF1R Inhibitor
Authors: McCaffery Ian , Tudor Yanyan , Deng Hongjie , Tang Rui , Suzuki Samuel , Badola Sunita , Kindler Hedy L. , Fuchs Charles S. , Loh Elwyn , Patterson Scott D. , Chen Li , Gansert Jennifer L.
Published: April 2023

PDF - 35K, Circulating biomarker distribution across arms.
Supplementary Figure Legends from Accessory Cells of the Microenvironment Protect Multiple Myeloma from T-Cell Cytotoxicity through Cell Adhesion-Mediated Immune Resistance
Authors: de Haart Sanne J. , van de Donk Niels W.C.J. , Minnema Monique C. , Huang Julie H. , Aarts-Riemens Tineke , Bovenschen Niels , Yuan Huipin , Groen Richard W.J. , McMillin Douglas W. , Jakubikova Jana , Lokhorst Henk M. , Martens Anton C. , Mitsiades Constantine S. , Mutis Tuna
Published: April 2023

Supplementary Figure Legends - PDF file 73K, Legends for supplementary figures
Supplementary Figures 1 - 3, Table 1 from Selective JAK2 Inhibition Specifically Decreases Hodgkin Lymphoma and Mediastinal Large B-cell Lymphoma Growth In Vitro and In Vivo
Authors: Hao Yansheng , Chapuy Bjoern , Monti Stefano , Sun Heather H. , Rodig Scott J. , Shipp Margaret A.
Published: April 2023

PDF file - 5154KB, Table S1. Fedra'nib EC50 in the cHL and MLBCL cell lines. Figure S1. Immunohistochemical signature of chemical JAK2 inhibition in cHL and MLBCL cell lines. Figure S2. Transcript abundance of PIM1 in cHL and MLBCL cell lines. Figure S3. Tolerability study of fedra?nib in NSG mice.
Supplementary Figure 4 from Accessory Cells of the Microenvironment Protect Multiple Myeloma from T-Cell Cytotoxicity through Cell Adhesion-Mediated Immune Resistance
Authors: de Haart Sanne J. , van de Donk Niels W.C.J. , Minnema Monique C. , Huang Julie H. , Aarts-Riemens Tineke , Bovenschen Niels , Yuan Huipin , Groen Richard W.J. , McMillin Douglas W. , Jakubikova Jana , Lokhorst Henk M. , Martens Anton C. , Mitsiades Constantine S. , Mutis Tuna
Published: April 2023

Supplementary Figure 4 - PDF file 219K, FasL upregulation on CTLs upon MM cell recognition is not hampered by presence of accessory cells. CD4+ (A) and CD8+ (B) CTLs were cultured alone (unstimulated) or in the presence of tumor cells and in presence or absence of accessory cells as indicated. After 3 hours of co-incubation CTLs were evaluated for CD178 (Fas ligand) expression. Percentage of FasL expressing cells is indicated
Supplementary Table 1 from The Severity of Neural Invasion Is Associated with Shortened Survival in Colon Cancer
Authors: Liebl Florian , Demir Ihsan Ekin , Rosenberg Robert , Boldis Alexandra , Yildiz Esra , Kujundzic Kristina , Kehl Timo , Dischl Dominic , Schuster Tibor , Maak Matthias , Becker Karen , Langer Rupert , Laschinger Melanie , Friess Helmut , Ceyhan Güralp O.
Published: April 2023

PDF file - 62K, Supplementary Table with patient characteristics
Supplementary Figure 1 from Targeting Protein Kinase CK2 Suppresses Prosurvival Signaling Pathways and Growth of Glioblastoma
Authors: Zheng Ying , McFarland Braden C. , Drygin Denis , Yu Hao , Bellis Susan L. , Kim Hyunsoo , Bredel Markus , Benveniste Etty N.
Published: April 2023

PDF file - 104K, Supplemental Figure 1. Localization of CK2 in GBM Tumor and Mouse Brain, and in GBM Cells.
Supplementary Figure 5 from A 3-Plex Methylation Assay Combined with the FGFR3 Mutation Assay Sensitively Detects Recurrent Bladder Cancer in Voided Urine
Authors: Kandimalla Raju , Masius Roy , Beukers Willemien , Bangma Chris H. , Orntoft Torben F. , Dyrskjot Lars , van Leeuwen Nikki , Lingsma Hester , van Tilborg Angela A.G. , Zwarthoff Ellen C.
Published: April 2023

PDF file, 15K, ROC curve of methylation assay (dotted line) and methylation + FGFR3 assay (thick line) for the validation set.
Supplementary Tables 1 - 6 from Defining Risks of Taxane Neuropathy: Insights from Randomized Clinical Trials
Authors: Kudlowitz David , Muggia Franco
Published: April 2023

PDF file - 133K, Tables referenced in text that present clinical trials.
Supplementary Figure 3 from Identification of FGFR4 as a Potential Therapeutic Target for Advanced-Stage, High-Grade Serous Ovarian Cancer
Authors: Zaid Tarrik M. , Yeung Tsz-Lun , Thompson Melissa S. , Leung Cecilia S. , Harding Tom , Co Ngai-Na , Schmandt Rosie S. , Kwan Suet-Ying , Rodriguez-Aguay Cristian , Lopez-Berestein Gabriel , Sood Anil K. , Wong Kwong-Kwok , Birrer Michael J. , Mok Samuel C.
Published: April 2023

PDF file - 2288K, Validation of upregulated expression of genes identified via expression profiling of FGFR4-knockdown ovarian cancer cells
Supplementary Figure 5 from Inhibition of Protein Phosphatase 2A Radiosensitizes Pancreatic Cancers by Modulating CDC25C/CDK1 and Homologous Recombination Repair
Authors: Wei Dongping , Parsels Leslie A. , Karnak David , Davis Mary A. , Parsels Joshua D. , Marsh Amanda C. , Zhao Lili , Maybaum Jonathan , Lawrence Theodore S. , Sun Yi , Morgan Meredith A.
Published: April 2023

PDF file - 52K, LB100 causes an increase in pHistone H3 positive cells.
Supplementary Table 4 from Biomarker Analysis of Neoadjuvant Doxorubicin/Cyclophosphamide Followed by Ixabepilone or Paclitaxel in Early-Stage Breast Cancer
Authors: Horak Christine E. , Pusztai Lajos , Xing Guan , Trifan Ovidiu C. , Saura Cristina , Tseng Ling-Ming , Chan Stephen , Welcher Rosanne , Liu David
Published: April 2023

PDF file - 65K, Summary of gene models
Supplementary Figures 1 - 3 from BMN 673, a Novel and Highly Potent PARP1/2 Inhibitor for the Treatment of Human Cancers with DNA Repair Deficiency
Authors: Shen Yuqiao , Rehman Farah L. , Feng Ying , Boshuizen Julia , Bajrami Ilirjana , Elliott Richard , Wang Bing , Lord Christopher J. , Post Leonard E. , Ashworth Alan
Published: April 2023

PDF file - 150K, Supplementary Figure 1: BMN 673 induces DNA damage at lower doses and with higher intensity than olaparib. Supplementary Figure 2: BMN 673 is active in vivo against xenograft models with PTEN deficiency. Supplementary Figure 3: Balb/c nude mice carrying sc MDA-MB-468 xenograft tumors were treated with BMN673 at 0.33 mg/kg, QD or BMN673 at 0.165 mg/kg, BID for 28 consecutive days (Days 15-42 post tumor implantation) and the animals were terminated at Day 64 post tumor implantation.
Supplementary Figure Legend from A Potent Combination of the Novel PI3K Inhibitor, GDC-0941, with Imatinib in Gastrointestinal Stromal Tumor Xenografts: Long-Lasting Responses after Treatment Withdrawal
Authors: Floris Giuseppe , Wozniak Agnieszka , Sciot Raf , Li Haifu , Friedman Lori , Van Looy Thomas , Wellens Jasmien , Vermaelen Peter , Deroose Christophe M. , Fletcher Jonathan A. , Debiec-Rychter Maria , Schöffski Patrick
Published: April 2023

PDF file - 240K
Supplementary Text 2 from A Molecular Taxonomy for Urothelial Carcinoma
Authors: Sjödahl Gottfrid , Lauss Martin , Lövgren Kristina , Chebil Gunilla , Gudjonsson Sigurdur , Veerla Srinivas , Patschan Oliver , Aine Mattias , Fernö Mårten , Ringnér Markus , Månsson Wiking , Liedberg Fredrik , Lindgren David , Höglund Mattias
Published: April 2023

PDF file - 1.8MB, Detailed description of gene expression signatures
Supplementary Figure 8 from Molecular Photoacoustic Imaging of Follicular Thyroid Carcinoma
Authors: Levi Jelena , Kothapalli Sri-Rajashekar , Bohndiek Sarah , Yoon Joon-Kee , Dragulescu-Andrasi Anca , Nielsen Carsten , Tisma Aleksandra , Bodapati Sunil , Gowrishankar Gayatri , Yan Xinrui , Chan Carmel , Starcevic Daniela , Gambhir Sanjiv Sam
Published: April 2023

PDF file - 866K, Photoacoustic and optical imaging of the probe cleavage in tumors with different levels of MMPs: HT1080 (high MMP) and BT20 (low MMP)
Supplementary Figure Legends from Onartuzumab (MetMAb): Using Nonclinical Pharmacokinetic and Concentration–Effect Data to Support Clinical Development
Authors: Xiang Hong , Bender Brendan C. , Reyes Arthur E. , Merchant Mark , Jumbe Nelson L. ‘Shasha’ , Romero Mally , Davancaze Teresa , Nijem Ihsan , Mai Elaine , Young Judy , Peterson Amy , Damico-Beyer Lisa A.
Published: April 2023

PDF file, 93K.
Supplementary Figure 6 from Onartuzumab (MetMAb): Using Nonclinical Pharmacokinetic and Concentration–Effect Data to Support Clinical Development
Authors: Xiang Hong , Bender Brendan C. , Reyes Arthur E. , Merchant Mark , Jumbe Nelson L. ‘Shasha’ , Romero Mally , Davancaze Teresa , Nijem Ihsan , Mai Elaine , Young Judy , Peterson Amy , Damico-Beyer Lisa A.
Published: April 2023

PDF file, 2424K, Observed individual concentration-time profile of onartuzumab in human in comparison with cyno-based prediction.
Supplementary Figure 4 from Onartuzumab (MetMAb): Using Nonclinical Pharmacokinetic and Concentration–Effect Data to Support Clinical Development
Authors: Xiang Hong , Bender Brendan C. , Reyes Arthur E. , Merchant Mark , Jumbe Nelson L. ‘Shasha’ , Romero Mally , Davancaze Teresa , Nijem Ihsan , Mai Elaine , Young Judy , Peterson Amy , Damico-Beyer Lisa A.
Published: April 2023

PDF file, 3179K, Representative for visual predictive check.
Supplementary Figure 3 from Molecular Photoacoustic Imaging of Follicular Thyroid Carcinoma
Authors: Levi Jelena , Kothapalli Sri-Rajashekar , Bohndiek Sarah , Yoon Joon-Kee , Dragulescu-Andrasi Anca , Nielsen Carsten , Tisma Aleksandra , Bodapati Sunil , Gowrishankar Gayatri , Yan Xinrui , Chan Carmel , Starcevic Daniela , Gambhir Sanjiv Sam
Published: April 2023

PDF file - 159K, Cleavage specificity
Supplementary Figure 3 from Onartuzumab (MetMAb): Using Nonclinical Pharmacokinetic and Concentration–Effect Data to Support Clinical Development
Authors: Xiang Hong , Bender Brendan C. , Reyes Arthur E. , Merchant Mark , Jumbe Nelson L. ‘Shasha’ , Romero Mally , Davancaze Teresa , Nijem Ihsan , Mai Elaine , Young Judy , Peterson Amy , Damico-Beyer Lisa A.
Published: April 2023

PDF file, 1651K, Representative individual fits.
Supplementary Figure 2 from Onartuzumab (MetMAb): Using Nonclinical Pharmacokinetic and Concentration–Effect Data to Support Clinical Development
Authors: Xiang Hong , Bender Brendan C. , Reyes Arthur E. , Merchant Mark , Jumbe Nelson L. ‘Shasha’ , Romero Mally , Davancaze Teresa , Nijem Ihsan , Mai Elaine , Young Judy , Peterson Amy , Damico-Beyer Lisa A.
Published: April 2023

PDF file, 2444K, Basic goodness-of-fit plots for PK-PD modeling in KP4 tumor-bearing mice.
Supplementary Figures from Therapeutic Enhancement of ER Stress by Insulin-Like Growth Factor I Sensitizes Myeloma Cells to Proteasomal Inhibitors
Authors: Tagoug Inès , Jordheim Lars Petter , Herveau Stéphanie , Matera Eva-Laure , Huber Anne-Laure , Chettab Kamel , Manié Serge , Dumontet Charles
Published: April 2023

PDF file - 464K, Results shown are representative of three separate experiments (S1C, S2, S3A) and mean values from 3 independent experiments +/- SD (S1A-B, S4)
Supplementary Figure Legends from Electrocardiographic Studies of Romidepsin Demonstrate Its Safety and Identify a Potential Role for KATP Channel
Authors: Noonan Anne M. , Eisch Robin A. , Liewehr David J. , Sissung Tristan M. , Venzon David J. , Flagg Thomas P. , Haigney Mark C. , Steinberg Seth M. , Figg William D. , Piekarz Richard L. , Bates Susan E.
Published: April 2023

Supplementary Figure Legends - PDF file 25K, Legends describing supplementary figures
Supplementary Table 1 from A Single Nucleotide Polymorphism in Inflammatory Gene RNASEL Predicts Outcome after Radiation Therapy for Localized Prostate Cancer
Authors: Schoenfeld Jonathan D. , Margalit Danielle N. , Kasperzyk Julie L. , Shui Irene M. , Rider Jennifer R. , Epstein Mara M. , Meisner Allison , Kenfield Stacey A. , Martin Neil E. , Nguyen Paul L. , Kantoff Philip W. , Giovannucci Edward L. , Stampfer Meir J. , Mucci Lorelei A.
Published: April 2023

PDF file - 54K, Univariate associations with time to composite outcome